Operational Highlights (Gurgaon Standalone)

  • IP volumes increased 11.4% YoY to 9,181 patients in Q1 FY27
  • Average Revenue Per Occupied Bed (ARPOB) reached ₹85,690, up 7.4% YoY
  • Occupancy improved to 65.7%, representing a 443 basis points increase YoY
  • Average Length of Stay (ALOS) reduced to 3.54 days from 3.67 days YoY
  • Operational bed capacity remained stable at 544 beds
  • International patients contributed 27-30% of revenue, among highest in listed hospital sector
  • Patient base spans over 150+ countries with established partnerships across Africa, CIS, Middle East and SAARC nations

Financial Performance (Standalone)

  • Revenue from operations grew 15.4% YoY to ₹27,849 lacs in Q1 FY27
  • EBITDA increased 24.4% YoY to ₹6,163 lacs
  • EBITDA margin expanded 160 bps to 22.1%
  • PAT grew 32.7% YoY to ₹3,306 lacs
  • PAT margin improved to 11.9% from 10.3% last year
  • Other income declined due to utilization of IFC funds towards expansion projects

Financial Performance (Consolidated)

  • Revenue from operations grew 12.7% YoY to ₹28,732 lacs
  • EBITDA increased 27.9% YoY to ₹6,182 lacs
  • EBITDA margin expanded 256 bps YoY to 21.5%
  • PAT grew 48.3% YoY to ₹3,144 lacs
  • PAT margin improved to 10.9% from 8.3% last year
  • Basic EPS increased 46.7% YoY to ₹1.98
  • Diluted EPS increased 46.7% YoY to ₹1.98

Expansion and Growth Initiatives

  • 300+ bed Raipur super speciality hospital commenced operations in July 2026
  • 650+ bed South Delhi hospital planned through long-term 30-year operating agreement (expected operational date: Q4 FY2029)
  • Bed capacity roadmap to expand to ~2,000 beds over next 3-5 years
  • Gurgaon hospital received Platinum Green Building Certification enabling 15% increase in FAR, potentially adding ~100 beds
  • Additional FAR purchase to 2.15 could add another ~200 beds, taking Gurgaon capacity to 950-1,000 beds
  • Proposed ~₹700 crore fund raise approved by shareholders to fund growth initiatives

Clinical Capabilities and Accreditations

  • 14 Centres of Excellence across 40+ specialties
  • ~60% of revenue from high-acuity specialties supporting premium realizations
  • Market-leading expertise in oncology, transplants, robotic surgery and advanced critical care
  • Strategic partnership with KIMS to establish Heart & Lung Transplant programme
  • Completed 2,500+ CyberKnife radiosurgery procedures
  • North India's first CyberKnife M6 with VOLO technology installed

Management and Governance

  • Chairman: Mr. Onkar Kanwar
  • Managing Director: Dr. Devlina Chakravarty
  • Board includes 10 directors with 5 independent directors
  • Core management team led by CFO Sanjiv Kumar Kothari and other functional heads

Shareholding Pattern (as of June 30, 2026)

  • Promoters (Constructive Finance Pvt Ltd): 58.4%
  • International Finance Corporation: 12.0%
  • Government of Kerala: 4.3%
  • Dr. Devlina Chakravarty (Director): 2.9%
  • Kerala State Industrial Development Corporation: 1.9%
  • Various institutional and retail investors holding remaining shares